| __timestamp | Amphastar Pharmaceuticals, Inc. | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 159205000 | 22732000 |
| Thursday, January 1, 2015 | 174172000 | 29245000 |
| Friday, January 1, 2016 | 150976000 | 33206000 |
| Sunday, January 1, 2017 | 149380000 | 31152000 |
| Monday, January 1, 2018 | 187681000 | 10136000 |
| Tuesday, January 1, 2019 | 190434000 | 45546000 |
| Wednesday, January 1, 2020 | 206506000 | 43367000 |
| Friday, January 1, 2021 | 238029000 | 81413000 |
| Saturday, January 1, 2022 | 250127000 | 139304000 |
| Sunday, January 1, 2023 | 293274000 | 192361000 |
Unveiling the hidden dimensions of data
In the competitive landscape of biopharmaceuticals, understanding cost dynamics is crucial. Over the past decade, Amphastar Pharmaceuticals, Inc. and Halozyme Therapeutics, Inc. have shown distinct trends in their cost of revenue. Amphastar's cost of revenue has surged by approximately 84% from 2014 to 2023, reflecting its expanding operations and market reach. In contrast, Halozyme's cost of revenue skyrocketed by an astonishing 747% during the same period, indicating a significant shift in its business model or product offerings.
These trends highlight the strategic decisions each company has made in response to market demands and technological advancements. As of 2023, Amphastar's cost of revenue stands at nearly 293 million, while Halozyme's is close to 192 million, showcasing their differing scales and operational focuses. This data provides a fascinating glimpse into the financial strategies of these industry leaders.
Analyzing Cost of Revenue: Johnson & Johnson and Amphastar Pharmaceuticals, Inc.
Cost of Revenue Trends: Amgen Inc. vs Halozyme Therapeutics, Inc.
Cost of Revenue Trends: Sanofi vs Amphastar Pharmaceuticals, Inc.
Cost of Revenue Trends: Bristol-Myers Squibb Company vs Halozyme Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Gilead Sciences, Inc. vs Halozyme Therapeutics, Inc.
Cost of Revenue Trends: BioMarin Pharmaceutical Inc. vs Halozyme Therapeutics, Inc.
Cost of Revenue: Key Insights for Halozyme Therapeutics, Inc. and Corcept Therapeutics Incorporated
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Veracyte, Inc.'s Expenses
Cost of Revenue: Key Insights for Halozyme Therapeutics, Inc. and HUTCHMED (China) Limited
Comparing Cost of Revenue Efficiency: Veracyte, Inc. vs Amphastar Pharmaceuticals, Inc.
MorphoSys AG vs Amphastar Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Amphastar Pharmaceuticals, Inc. and Evotec SE